PRINCEPS data point to feasibility of neoadjuvant atezolizumab in NSCLC

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 21 / Springer Healthcare

PRINCEPS data point to feasibility of neoadjuvant atezolizumab in NSCLC

Institut Gustave Roussy, Villejuif, France

Oncology Lung Cancer Cancer Immunotherapy ESMO-2020

Description

Benjamin Besse outlines their phase 2 trial results supporting the further investigation of neoadjuvant atezolizumab followed by surgery in individuals with resectable non-small-cell lung cancer.

Related Content

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.